Otsuka Pharmaceuticals, Inc.

Amwell Underscores Commitment to Driving Positive Impact with Environmental, Social and Governance Framework
VillageMD Acquires Summit Health-CityMD, Creating One of the Largest Independent Provider Groups in the U.S.
Cigna Medical Group to Expand Health Services to More People, Changes Name to Evernorth Care Group
Enters Strategic Collaboration with VillageMD to Accelerate Value-Based Services and Care Delivery Strategy
Amwell Announces Appointment of Robert Webb to its Board of Directors

Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia
Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients
FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia